Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 7/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.46 |
| ▸ | RET | P07949 | 9/20 | 0.45 |
| ▸ | ROS1 | P08922 | 9/20 | 0.45 |
| ▸ | FLT3 | P36888 | 9/20 | 0.45 |
| ▸ | JAK1 | P23458 | 5/20 | 0.43 |
| ▸ | JAK3 | P52333 | 5/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29229026 | 0.76 | CXCR2 (0.51) | JAK1JAK3PDE4BCXCR2 | |
| SCHEMBL17766551 | 0.75 | JAK1 (0.53) | JAK1JAK3PDE4BJAK2CXCR2 | |
| SCHEMBL29447250 | 0.75 | ALK (0.53) | EML4ALKRETROS1FLT3 | |
| SCHEMBL17848239 | 0.75 | ALK (0.53) | EML4ALKRETROS1FLT3 | |
| SCHEMBL3081421 | 0.73 | NPC1 (0.70) | PARP1 | |
| SCHEMBL18142882 | 0.72 | F10 (0.39) | EML4ALKRETROS1FLT3 | |
| SCHEMBL3683008 | 0.72 | PDE4B (0.47) | JAK1JAK3PDE4BCXCR2 | |
| SCHEMBL3436295 | 0.72 | NPC1 (0.51) | PARP1 | |
| SCHEMBL3434271 | 0.72 | KDM4E (0.52) | PARP1 | |
| SCHEMBL4781886 | 0.72 | HSP90AA1 (0.44) | JAK1JAK3PDE4BCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233840-A1 | HETEROCYCLIC DERIVATIVES MODULATING ACTIVITY OF CERTAIN PROTEIN KINASES | Eudendron S.r.l. (IT) | 2017-10-25 | — | — | EP | claimed |
| WO-2016096709-A1 | HETEROCYCLIC DERIVATIVES MODULATING ACTIVITY OF CERTAIN PROTEIN KINASES | EUDENDRON S.R.L. (IT) | 2016-06-23 | — | — | WO | claimed |
| US-20200325122-A1 | CRYSTALLINE FORM OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-10-15 | — | — | US | disclosed |
| US-10398693-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190022089-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3227276-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROBLASTOMA | Ignyta, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-3227686-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | Ignyta, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089760-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROBLASTOMA | IGNYTA, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089853-A1 | MULTIPLEXED IMMUNOHISTOCHEMISTRY ASSAYS FOR DIAGNOSIS AND TREATMENT OF CANCER | IGNYTA, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2668184-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | Pierre Fabre Medicament (FR) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101239-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398693-B2 | Pharmaceutical compositions and dosage forms | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | EML4 3790/4885ALK 1518/4885RET 2605/4885 |
| US-20200325122-A1 | CRYSTALLINE FORM OF N-[5-(3,5-DIFLUORO-BENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYL-PIPERAZIN-1-YL)-2-(TETRAHYDRO-PYRAN-4-YLAMINO)-BENZAMIDE | CSNK2A1, CSNK2A2, CSNK1A1 | EML4 2409/4885ALK 932/4885RET 751/4885 |
| US-20190022089-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | EML4 3790/4885ALK 1518/4885RET 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.